Paris, France

Jean-Pierre Raynaud


Average Co-Inventor Count = 2.1

ph-index = 6

Forward Citations = 150(Granted Patents)


Company Filing History:


Years Active: 1980-2003

Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jean-Pierre Raynaud

Introduction

Jean-Pierre Raynaud is a notable inventor based in Paris, France. He has made significant contributions to the field of medicine, particularly in the treatment of prostate cancer. With a total of 12 patents to his name, Raynaud's work has had a profound impact on medical research and treatment methodologies.

Latest Patents

Among his latest patents is the innovative use of a Serenoa repens extract for the production of a medicament aimed at treating prostate cancer. This invention involves a lipido-sterolic extract that can be administered either in isolation or in conjunction with prostatectomy, radiotherapy, and/or hormonotherapy. The goal is to prevent and treat prostate cancer effectively. Another significant patent details a method of treating prostate cancer in warm-blooded animals, which includes administering an effective amount of a specific peptide and an anti-androgen.

Career Highlights

Throughout his career, Jean-Pierre Raynaud has worked with prominent companies such as Roussel Uclaf and Pierre Fabre Medicament. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Raynaud has collaborated with esteemed professionals in his field, including Fernand Labrie and Pierre Fabre. These partnerships have further enhanced his research and development efforts, leading to groundbreaking inventions.

Conclusion

Jean-Pierre Raynaud's contributions to medical innovation, particularly in the treatment of prostate cancer, highlight his importance as an inventor. His patents and collaborations reflect a commitment to improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…